Results 211 to 220 of about 100,948 (293)

Is There a Market for Organic Milk in Serbia? Insights From Integrated Choice and Latent Variable Model

open access: yesAgribusiness, EarlyView.
ABSTRACT Past growth in the global organic market has been concentrated in high‐income countries, while in middle‐income countries such as Serbia the organic market remains nascent and characterized by a sparse assortment of organic products, high retail premia and limited evidence on consumer preferences and their drivers.
Milan Tatic   +3 more
wiley   +1 more source

Evaluation of multimodal large language models for psoriasis diagnosis, severity grading, and treatment recommendations from clinical photographs: ChatGPT shows superior performance compared to other large language models. [PDF]

open access: yesFront Med (Lausanne)
Boostani M   +15 more
europepmc   +1 more source

Annual Report of the 2022 National Clinical Database: Decade‐Long Trends and Current Status of Gastroenterological Surgery in Japan

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
ABSTRACT Aim The National Clinical Database (NCD) of Japan is the largest nationwide registry, covering over 95% of surgeries in the country. This 2022 annual report summarizes the short‐term outcomes of gastroenterological surgeries and discusses trends and insights over the past decade.
Koshi Kumagai   +19 more
wiley   +1 more source

Essential Updates 2024–2025: Surgical Strategy for Esophageal Cancer Toward a New Paradigm in the Era of Immunotherapy and Personalization

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
This review summarizes key advances from 2024 to 2025 that are reshaping esophageal cancer surgery toward a strategy‐oriented, personalized paradigm through the integration of immunotherapy, population aging, and intelligent technologies. Adjuvant nivolumab after neoadjuvant chemoradiotherapy remains the only perioperative approach with durable benefit,
Shuichiro Oya   +2 more
wiley   +1 more source

Survival Outcomes of Gemcitabine–Cisplatin–S‐1 Versus Gemcitabine–Cisplatin in Unresectable Biliary Tract Cancer: A Multicenter Retrospective Study With a Focus on Conversion Surgery

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
In this multicenter retrospective study conducted by the Biliary Tract Club, we compared survival outcomes between gemcitabine–cisplatin–S‐1 (GCS) and gemcitabine–cisplatin (GC) in patients with unresectable biliary tract cancer, with a particular focus on conversion surgery. GCS was associated with longer overall and progression‐free survival compared
Hisashi Kosaka   +27 more
wiley   +1 more source

Home - About - Disclaimer - Privacy